The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
travoprost intracameral
3 marketed package NDCs · 2 active manufacturers
Most dispensed: TRAVOPROST 75 ug · Implant · #1 pouch/carton / 1 tray in 1 pouch / 1 canister in 1 tray / 1 implant in 1 canister
Same drug class
Other molecules FDA puts in Prostaglandin Analog, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
- tafluprost opthalmic· 1 maker
- travoprost (isomer free)· 1 maker
- travoprost ophthalmic solution usp, 0.004%· 1 maker
- travoprost ophthalmic solution, 0.004%· 1 maker
- travoprost ophthalmic· 2 makers
- travoprost ophthalmic solution· 4 makers
- dinoprostone· 7 makers
- tafluprost· 12 makers
- travoprost· 16 makers
- alprostadil· 18 makers
- carboprost tromethamine· 26 makers
- bimatoprost· 38 makers
Common questions
- Is Travoprost intracameral in shortage right now?
- No. FDA does not currently list Travoprost intracameral in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Travoprost intracameral?
- 2 companies have marketed Travoprost intracameral in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.